OncoSec Medical

OncoSec Medical R&D per Employee

Delisted

The R&D Spending per Employee of OncoSec Medical (ONCS) as of Oct 20, 2026 is 614,798.64 USD. In the previous year, R&D Spending per Employee was 811,848.57 USD — a change of -24.27% (lower).

R&D per Employee

614,798.64USD

YoY

-24.27%

Last updated:

R&D Spending per Employee of OncoSec Medical is 2022 614,798.64 USD. R&D Spending per Employee of OncoSec Medical was 2021 811,848.57 USD. It decreases by -24.27% lower compared to the previous year.

The OncoSec Medical R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2015
312,688.05 USD
Jan 1, 2016
350,992.71 USD
Jan 1, 2017
284,589.24 USD
Jan 1, 2018
414,655.24 USD
Jan 1, 2019
439,171.38 USD
Jan 1, 2020
597,543.26 USD
Jan 1, 2021
811,848.57 USD
Jan 1, 2022
614,798.64 USD
The OncoSec Medical R&D per Employee history
YEARR&D per EmployeeYoY
614,798.64USD-24.27%
811,848.57USD+35.86%
597,543.26USD+36.06%
439,171.38USD+5.91%
414,655.24USD+45.70%
284,589.24USD-18.92%
350,992.71USD+12.25%
312,688.05USD+126.57%
138,008.26USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OncoSec Medical Stock analysis

What does OncoSec Medical do? OncoSec Medical Inc is a US-based company specializing in the development of cancer treatment methods through immunotherapy. The company was founded in 2011 and is headquartered in San Diego, California. The history of OncoSec Medical Inc began with the idea of improving tumor treatments through electroporation. Electroporation is a process that uses electric pulses to increase the permeability of cell membranes. This facilitates the exchange of molecules and the uptake of drugs, which is used in the treatment of cancer cells. The business model of OncoSec Medical Inc is based on the development and commercialization of immunotherapies to combat cancer. Electroporation is used to locally infect tumor lesions with reactivated T-cells and other immune cells to generate an immune response. OncoSec Medical Inc has developed a proprietary platform called ImmunoPulse, which combines electroporation and immunotherapy. The company is divided into various divisions, including research and development, clinical trials, manufacturing, and distribution. Research and development focus on identifying potential immunotherapies and testing drug candidates. Clinical trials are designed to confirm the effectiveness and safety of therapies through clinical testing. Manufacturing involves the production of drug candidates and clinical preparations in accordance with Good Manufacturing Practices (GMPs). Distribution includes the sale and marketing of approved therapies to patients and healthcare providers. OncoSec Medical Inc offers a variety of immunotherapies for the treatment of various types of cancer. This includes ImmunoPulse IL-12 therapy, which is used to treat metastatic melanoma. The company is also working on several other therapies, including the Verapamil-Plus-IL-2 protocol for the treatment of breast and prostate cancer. In summary, OncoSec Medical Inc is an emerging biotechnology company specializing in the development and commercialization of immunotherapies to combat cancer. Through its proprietary ImmunoPulse platform and extensive research and development, the company strives to provide effective and safe treatment options for cancer patients, fully harnessing the potential of immunotherapy. OncoSec Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OncoSec Medical stock

R&D Spending per Employee of OncoSec Medical is 614,798.64 USD in 2022.

R&D Spending per Employee of OncoSec Medical changed from 811,848.57 USD to 614,798.64 USD, representing a -24.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee OncoSec Medical since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's OncoSec Medical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — OncoSec Medical

All Key Metrics — OncoSec Medical